FC101 as a method of treatment for cancer
AssigneeUniversity of South Carolina
InventorsRoy E. Wuthier, Daotai Nie
Life of this patent
Estimating the term…
Abstract
The present invention provides a treatment for angiogenic diseases, including solid tumors. The treatment consists of administering therapeutically active dosages of FC101, resulting in a reduction in endothelial cell proliferation and inhibition of new blood vessel formation. FC101 can also be used as a lead compound to develop other pharmacologically-active compounds, by adding or substituting different functional groups for those already present on the FC101 molecule.
Claims12
A method for treating cancer sensitive to the compounds below in a patient, comprising administering to said patient a therapeutically active dosage of a composition comprising 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one, wherein said composition is administered via a pharmaceutically or veterinarily acceptable carrier.
A method for inhibiting metastasis sensitive to the compounds below in a patient, comprising administering to said patient a therapeutically active dosage of a composition comprising 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one, wherein said composition is administered via a pharmaceutically or veterinarily acceptable carrier.
Dependencies are inferred from the claim text.